Novo Nordisk

Novo Nordisk dominates the global market for diabetes and obesity treatments, with its GLP-1 receptor agonists Ozempic and Wegovy driving it to become Europe's most valuable publicly traded company. The firm's century-long mastery of biological manufacturing and peptide chemistry represents a concentration of pharmaceutical capability that is difficult to replicate. Novo Nordisk anchors the Copenhagen-Medicon Valley life sciences cluster and demonstrates that European companies can lead globally in biotech when deep science is paired with disciplined industrial scaling.